Alhambra A, Cuadros J A, Cacho J, Gómez-Garcés J L, Alós J I
Department of Microbiology, Hospital de Móstoles, 28935 Móstoles, Madrid, Spain.
J Antimicrob Chemother. 2004 Jun;53(6):1090-4. doi: 10.1093/jac/dkh218. Epub 2004 Apr 29.
The treatment of complicated urinary tract infections may require the use of a parenteral antibiotic with potent activity against the most common urinary pathogens. Ertapenem is a broad-spectrum 1beta-methyl carbapenem with a long plasma half-life that allows administration of a single daily dose.
The purpose of this work was to test the in vitro susceptibility to ertapenem, ampicillin, cefazolin, cefuroxime, cefotaxime, co-amoxiclav, piperacillin/tazobactam, imipenem, gentamicin, amikacin, fosfomycin, ciprofloxacin and co-trimoxazole of 482 strains of urinary pathogens of the family Enterobacteriaceae isolated from patients in the community of Madrid (40% from males). The distribution was as follows: Escherichia coli (n = 315), Proteus mirabilis (n = 42), Klebsiella spp. (n = 14) and AmpC-producing Enterobacteriaceae (n = 111). The strains studied were selected based on their resistance to quinolones and aminoglycosides, and their production of extended-spectrum beta-lactamases (ESBLs) or AmpC-type beta-lactamases.
All the strains were susceptible to ertapenem, imipenem and amikacin. The MIC(90) of ertapenem ranged from a minimum of 0.03 mg/L for Proteus vulgaris and a maximum of 1 mg/L for Enterobacter spp. Ertapenem was the most active of all drugs tested in all cases. On comparing antibiotic resistance among ESBL-producing strains of E. coli (n = 35) and E. coli strains not producing ESBLs (n = 280), statistically significant differences were obtained for ciprofloxacin (P = 0.002) and gentamicin (P = 0.011). Regarding ertapenem, only a slight increase in MIC(50) was seen, the value being 0.015 mg/L for strains not producing ESBLs versus 0.03 mg/L for ESBL-producing strains.
In view of its significant antibiotic potency against antibiotic-resistant Enterobacteriaceae, ertapenem may constitute a good therapeutic alternative in urinary infections caused by these pathogens.
复杂性尿路感染的治疗可能需要使用对最常见尿路病原体具有强效活性的胃肠外抗生素。厄他培南是一种广谱的1β-甲基碳青霉烯类抗生素,血浆半衰期长,允许每日单次给药。
本研究的目的是检测从马德里社区患者中分离出的482株肠杆菌科尿路病原体对厄他培南、氨苄西林、头孢唑林、头孢呋辛、头孢噻肟、阿莫西林/克拉维酸、哌拉西林/他唑巴坦、亚胺培南、庆大霉素、阿米卡星、磷霉素、环丙沙星和复方新诺明的体外敏感性。这些病原体分布如下:大肠埃希菌(n = 315)、奇异变形杆菌(n = 42)、克雷伯菌属(n = 14)和产AmpC酶的肠杆菌科细菌(n = 111)。所研究的菌株是根据它们对喹诺酮类和氨基糖苷类的耐药性以及它们产生超广谱β-内酰胺酶(ESBLs)或AmpC型β-内酰胺酶来选择的。
所有菌株对厄他培南、亚胺培南和阿米卡星均敏感。厄他培南的MIC90范围为,普通变形杆菌最低为0.03 mg/L,肠杆菌属最高为1 mg/L。在所有测试病例中,厄他培南是所有药物中活性最强的。比较产ESBLs的大肠埃希菌菌株(n = 35)和不产ESBLs的大肠埃希菌菌株(n = 280)之间的抗生素耐药性,环丙沙星(P = 0.002)和庆大霉素(P = 0.011)有统计学显著差异。关于厄他培南,仅观察到MIC50略有增加,不产ESBLs的菌株值为0.015 mg/L,产ESBLs菌株为0.03 mg/L。
鉴于厄他培南对耐药肠杆菌科细菌具有显著的抗生素效力,它可能是这些病原体引起的尿路感染的一种良好治疗选择。